

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

H. J. P. J. C. 68
SNT
1-09-01
PATENT
P239US00

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Thomas NILSSON et al. 
Appl. No.: 09/664,385 Group: 3721
Filed: September 18, 2000 Examiner: UNASSIGNED
For: METERED ELECTRO-DOSE

L E T T E R

Assistant Commissioner for Patents
Washington, DC 20231

Date: November 30, 2000

Sir:

Under the provisions of 35 U.S.C. § 119 and 37 C.F.R. § 1.55(a), the applicant(s) hereby claim(s) the right of priority based on the following application(s):

Country	Application No.	Filed
SWEDEN	0003082-5	August 31, 2000

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By 
Robert J. Patch, #17,355


RJP:mdp
P239US00

745 South 23rd Street, Suite 200
Arlington, Virginia 22202
(703) 521-2297

Attachment

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen



Intyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.



(71) Sökande Microdrug AG, Hergiswil NW CH
Applicant (s)

(21) Patentansökningsnummer 0003082-5
Patent application number

(86) Ingivningsdatum 2000-08-31
Date of filing

Stockholm, 2000-11-09

För Patent- och registreringsverket
For the Patent- and Registration Office

Therese Friberger
Therese Friberger

Avgift
Fee 170:-

RECEIVED
DEC - 14 2000
TECHNOLOGY CENTER 3700

PATENT- OCH
REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

2000 -08- 3 1

Huvudfaxen Kassan

Metered electro-dose**TECHNICAL FIELD**

The present invention relates to electrostatic dosing and more particularly to an electro-dose using electro-powder as well as a process and a method for preparation of a metered electro-dose for inhalation into the deep or upper lungs by means of an inhaler device.

BACKGROUND

The dosing of drugs is carried out in a number of different ways in the medical service today. Within health care more and more is focused on the possibility of dosing medical drugs as a powder directly to the airways and lungs of a patient by means of an inhaler in order to obtain an effective, quick and patient-friendly administration of such substances.

A dry powder inhaler, DPI, represents a device intended for administration of powder into the deep or upper lung airways by oral inhalation. With deep lung should be understood the peripheral lung and alveoli, where direct transport of active substance to the blood can take place. Particle sizes, to reach into the deep lung, should be in a range 0.5 - 3 μm and for a local lung delivery in the range 3 - 5 μm . A larger grain size will easily stick in the mouth and throat, and a smaller grain size may accompany the expiration air out again.

To succeed with systemic delivery of medical powders to the deep lung by inhalation there are some criteria, which have to be fulfilled. The most important is a very high degree of de-agglomeration of the medical powder but also an exact dose is of great importance. This is not possible with dry powder inhalers of today without special arrangements as for example a so called spacer.

By means of a spacer the small grains are evenly distributed in a container from which the inhalation can take place. Upon inhalation from the spacer the fine powder floating free in the air will effectively reach the alveoli of the

2000-08-31

2

Huvudfaxen Kassan

lung. This method in principle has two drawbacks, firstly difficulties to control the amount of medicine emitted to the lung as an uncontrolled amount of powder sticks to the walls of the spacer and secondly difficulties in handling the relatively space demanding apparatus.

5

Powders for inhalers have a tendency of agglomerating, in other word to clod or to form small or larger lumps, which then have to be de-agglomerated. De-agglomeration is defined as breaking up agglomerated powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is performed as a stage one during dosing and as a final stage 10 two during the patient's inspiration through the DPI.

15

Inhaler devices normally use the force exerted by the patient's more or less normal inspiration effort for de-agglomerating the medical substance administered when inhaling in an effort to bring as much as possible of the active substance into the lungs. This often leads to inhaler designs using high pressure drops, which will put the patient's lungpower to the test.

20

One major problem with some of the technique described above is to also obtain a low relative standard deviation (RSD) between doses with this type of technique due to lack of in line control possibilities in production making it hard to be in compliance with regulatory demands.

25

As already noted for an optimum amount of substance to reach the alveoli, an administered powder dose should preferably have a grain size between 0.5 and 3 µm. Besides, the inspiration must take place in a calm way to decrease air speed and thereby reduce deposition in the upper respiratory tracts.

30

Technologies to de-agglomerate today include advanced mechanical and aerodynamic systems and combinations between electrical and mechanical filling systems that can be seen in for instance in U.S. Patent No. 5,826,633. Further there are systems disclosed for dispersing aerosolized doses of

Huvudfaxen Kassan

medicaments, e.g. U.S. Patent No. 5,775,320, U.S. Patent No. 5,785,049, and U.S. Patent No. 5,740,794. Furthermore, in our International Publications WO 00/0636 and WO 00/6235 principles for de-agglomeration and classification are disclosed.

5

The term electro-powder refers to a micronized medical powder presenting controlled electrostatic properties to be suitable for electrostatic administration in an inhaler device. Such an electro-powder provides possibilities for a better dosing from electrostatically operating equipment 10 such as disclosed in our U.S. Patent No. 6,089,227 as well as our Swedish Patents No. 9802648-7 and 9802649-5, which present excellent inhalation dosing performance.

The state of the art also discloses a number of solutions for depositing 15 powder for dosing. U.S. Patent No. 6,063,194 discloses a powder deposition apparatus for depositing grains on a substrate using an electrostatic chuck having one or more collection zones and using an optical detection for quantifying the amount of grains deposited. U.S. Patent No. 5,714,007 and U.S. patent No. 6,007,630 disclose an apparatuses for electrostatically 20 depositing a medicament powder upon predefined regions of a substrate, the substrates being used to fabricate suppositories, inhalants, tablet capsules and the like. In U.S. Patent No. 5,699,649 and U.S. Patent No. 5,960,609 are presented metering and packaging methods and devices for pharmaceuticals and drugs, the methods using electrostatic phototechnology to package 25 microgram quantities of fine powders in discrete capsule and tablet form.

Devices of prior art technology does often not reach a sufficiently high degree of de-agglomeration and an exact dose is not well developed and leaves much to be desired when it comes to dosage conformity and lung deposition effectiveness of the medical substance. Therefore, there is still a demand of pre-fabricated high accuracy pre-metered doses to be loaded into an inhaler device, which then will ensure repeated exact doses to be given. The active 30 dry powder then must possess a fine particle fraction, which guarantees its

Huvudfaxen Kassan

administration to a position within the lung of a patient where it will exert its expected effect.

SUMMARY

5 An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a pre-metered medical powder intended for use in a dry powder inhaler and is formed from an electro-powder constituting an active powder substance or a dry powder medical formulation being onto a device member forming a dose carrier. The electro-
10 dose prepared from an electro-powder presenting a fine particle fraction (FPP) having of the order 50 % or more of its content with a particle size between 0.5-5 µm. The electro-powder of such a pre-metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 µC/g and presents a charge decay rate constant Q₅₀ of more than 0.1 sec with a tap density of less than
15 0.8 g/ml and a water activity a_w of less than 0.5.

The electro-dose porosity is adjusted by means of a mechanical and/or electrical vibration of the dose receiving device member during the electro-dose build-up operation to obtain an optimized porosity value of 75 to 99.9% calculated as $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$. A number of parameters must be kept under strict control during the processing in order to obtain the desired electro-dose for utilization in a dry powder inhaler.

25 An electro-dose according to the present invention is set forth by the independent claim 1 and the dependent claims 2 to 7. Furthermore a method for obtaining an electro-dose is set forth by the independent claim 8 and further embodiments of the method are set forth by the dependent claims 9 to 21. Also a process for the manufacturing of an electro-powder is set forth by the independent claim 22 and the dependent claims 23 to 31.
30

SHORT DESCRIPTION OF THE DRAWINGS

The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken together with the accompanying drawings, in which:

- FIG. 1 is a simplified flow chart for creating an electro-dose from an electro-powder;
- 10 FIG. 2 is a flow chart illustrating the powder dose analysis when preparing the electro-dose;
- FIG. 3 is a summary flow chart illustrating preparation of the electro-dose;
- 15 FIG. 4 illustrates a cross section of a dose carrier provided with a conducting or dissipative sheet for the preparation of an electro-dose by electrostatic methods;
- 20 FIG. 5 illustrates a cross section of a dose carrier made from a conductive or dissipative material for the preparation of an electro-dose by electrostatic methods;
- 25 FIG. 6 illustrates a cross section of a dose carrier containing a buried conductive material sheet inside an isolative material for the preparation of an electro-dose by means of electrostatic methods;
- 30 FIG. 7 illustrates a cross section of a dose carrier containing several separate buried conductive material sheets for the preparation of an electro-dose by electrostatic methods;
- FIG. 8 illustrates transfer of electro-powder to a carrier by means of an electrostatic field;

FIG. 9 illustrates transfer of electro-powder to the carrier by means of an electrostatic field and a focussing means;

5 FIG. 10 illustrates a control circuitry utilized in the transfer of powder according to FIG. 9;

FIG. 11 illustrates an applied alternating electric field as function of time in transferring powder particles to the carrier;

10 FIG. 12 illustrates displacement of carrier surface in micrometers as a function of time;

15 FIG. 13 illustrates a "tree" structure in an enlarged view initial positioning of de-agglomerated particles at the carrier surface;

FIG. 14 illustrates a "sponge" structure in an enlarged view of particles positioned at the carrier surface after a compaction operation;

20 FIG. 15 illustrates in an enlarged view of a "velvet" structure of the particles at the carrier surface;

FIG. 16 is graph representing dose porosity and de-agglomeration for particles of sizes 3 and 5 micrometers;

25 FIG. 17 is a graph representing calculation of de-agglomeration for particles up to 3 micrometers from an initial electro-powder particle size;

30 FIG. 18 is a graph representing calculation of de-agglomeration for particles up to 5 micrometers from an initial electro-powder particle size; and

2000-08-31

Huvudfaxon Kasson

FIG. 19 shows a measurement set-up used for a measurement of size distribution and mass and further calculation of deagglomeration and flow rate.

5

DESCRIPTION

In a starting step 100 of Figure 1 an electrostatically dosed electro-powder is brought into a powder dose analysis step 110. Dosing parameters are then determined in a step 120 to finally result in an electro-dose in a step 160. Electro-powder here is defined as a prepared active substance meeting a set 10 of electrical specifications for optimum electrostatic dosing properties. Specific charge is expressed in Coulomb per mass unit in this context as $\mu\text{C/g}$ after charging. Such an electro-powder should present an absolute specific charge, after charging by induction, corona, or tribo-charging, of the order of 0.1 to 25 $\mu\text{C/g}$ ($0.1 \times 10^{-6} - 25 \times 10^{-6}$ Coulomb/gram of negative or 15 positive charge) and a discharge rate constant $Q_{50} > 0.1$ sec. Q_{50} is defined as the time until 50% of the electrostatic charge is discharged, (for instance after a corona charging in an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD). Furthermore the electro-powder should constitute a powder with more than 50 % of fine particle fraction with a particle size 20 less than 5 μm and have a water content of less than 4 % together with a water activity $a_w < 0.5$, preferably being between 0.2 and 0.3 and a tap density of less than 0.8 g/ml.

25

Water content is defined as the amount of weakly bound water. It's calculated as the difference between the total water content, determined e.g. by Karl-Fischer titration, and the amount of strongly bound water, e.g. crystal water, characteristic for the substance. Water activity a_w is a dimensionless quantity, which may, for instance, be measured with an Aqualab model series 3 TE. Tap density is, for instance, measured by using 30 a Dual Autotap from Quantachrome[®] Corporation according to British Pharmacopoeia for Apparent Volume method. Both water activity and tap density are quantities well known to a person skilled in the field of chemistry analysis.

2000 -08- 3 1

Huvudfåxen Kassan

All measurements are performed at room temperature defined as in a range of 18 - 25°C in air or nitrogen atmosphere with a relative humidity less than 5 %. The absolute specific charge is the charge the electro-powder presents after an electrostatic charging being performed and subsequently measured 5 in µC/g with an electrometer, e.g. a Keithley Electrometer 6512 or an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD.

- The electro-dose is then defined as an electrostatically dosed electro-powder possessing the following specification: Porosity defined as $D_p^{\text{electro-dose}} = 100 - 10 \frac{\text{density}_{\text{electro-dose}}}{\text{density}_{\text{electro-powder}}} > 75 \%$ and having a optimized de-agglomeration of > 25 % and more preferable being more than 50 % and most preferable more than 75 % and meeting a dosage uniformity according to USP 24-NF 19 Supplement 601 Aerosols/Physical Tests pages 2674 - 2688, which will hereafter be referred to as USP, and also possessing a de-agglomeration difference measured according to USP compared with the de-agglomeration at a flow representing a pressure drop over the inhaler device reduced to 1 kPa ($1 - \frac{\text{de-agglomeration}(Q_{1\text{kPa}})}{\text{de-agglomeration}(Q)} \times 100 < 25 \%$ and more preferably less than 10 % and most preferably less than 5 %).
- 20 Particles intended for the deep lung, here defined as the peripheral lung and alveoli, where direct transport of an active substance to the blood can take place, should have a particle size in the range 0.5 - 3 µm. For treatment in the local lung, defined as upper parts of the lung, where treatment normally takes place for instance in asthma treatment, the particle size should be in the range 3-5 µm. All particle sizes are defined as the size of the particles measured with for instance a laser diffraction instrument e.g. a Malvern Mastersizer for physical size classification or an Andersen Impactor for an aerodynamic size classification and if not stated otherwise always referred to as aerodynamic particle size.
- 25 30 The active substance is a pharmaceutical active chemical or biological substance intended for administration into the deep or upper lung airways by oral inhalation from a dry powder inhaler device (DPI), where inhaled

Huvudfoxen Kassan

macromolecules could be from the following therapeutic areas: Insulin rapid intermediate and slow acting and diabetes peptides, interferons, interleukins and antagonists, antibodies, peptides for immune suppression, nerve growth factors, vaccines, gene therapies, genetically modified viroids and/or 5 bacterias, parathyroid hormone, osteoporosis peptides, antiobesity peptides, luteinizing hormone releasing hormone (LHRH) and LHRH analogs, somatostatin analogs, human calcitonin, colony stimulating factor, erythropoietins, growth hormones, erectile dysfunction, anti-pregnancy hormones.

10

The active substance also could be selected from the pharmaceutical active chemical and biological substances vasopressin, a vasopressin analogue, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, 15 growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, a somatostatin analogue, a gonadotropin agonist analogue, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, prolactin, an interleukin, a growth factor, a polypeptide vaccine, an enzyme, an endorphin, a glycoprotein, a lipoprotein kinas, intra-cellular 20 receptors, transcription factors, gene transcription activators/repressors, neurotransmitters (natural or synthetic), proteoglycans., a polypeptide involved in the blood coagulation cascade, that exerts its pharmacological effect systemically or any other polypeptide that has a molecular weight (Daltons) of up to 50 kDa or from the group consisting of proteins, 25 polysaccharides, lipids, nucleic acids and combinations thereof or from the group consisting of leuprolide and albuterol or is among opiates or nicotine and nicotine derivates or scopolamin, morphine, apomorphine analoges or equivalent active substances or pharmaceutical active chemicals for asthma treatment, e.g. budesonid, salbutamol, terbutalinsulphate, salmeterol, 30 flutikason, formoterol or salts thereof.

The first step **110** of the powder dose analysis includes a series of at least five powder doses to be analyzed in a step **210** illustrated in Figure 2.

Standard settings of the input parameters are then used, which are well spread over an interval to have a possibility to in a sequence of steps **220** to **270** determine the most important specifications regarding height, area, mass, porosity and dose de-agglomeration at flow rate Q according to USP and Q_{1kPa} . Very important is to determine if a porosity adjustment is necessary to be performed by active use of mechanical and/or electrical methods in the preparation of the electro-powder into an electro-dose by adjusting the dose porosity to an optimum giving an optimum inhalation performance regarding de-agglomeration. The porosity of the electro-dose is then defined as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ producing a measure in percent.

Dose height is then measured in step **220** for the powder doses of step **210** using for instance a Laser displacement sensor from Keyence LK-031 with electronics LK-2001 and cables LK-C2 giving the height of the powder bed in μm .

The electro-powder doses tested in step **210** are then brought to step **230** for dose area investigation, wherein the projected size of the powder dose onto the device member is measured with, e.g., a stereo microscope from Olympus and noted down in millimeters with a resolution of $100 \mu\text{m}$.

A machine script is a program to control a sequence of operations inside a feeding device 45 in Figure 8, which is a device that in a controlled way is feeding electrostatically charged electro-powder into an electrical field allowing selected electro-powder particles with the right particle size to be transported to the device member and having a set of parameters added to the script to control the flexible settings of a powder dose. This electrostatic dosing device **45** is also performing a control of the absolute specific charge and all other essential parameters, e.g. feeding rate of de-agglomerated electro-powder by the machine script. The dose de-agglomeration step **240** is defined as breaking up agglomerated electro-powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is

performed as a stage one during dosing of the electro-powder and as a final stage two during the patient's inspiration of the electro-dose through the DPI. De-agglomeration is measured, e.g. using a Malvern Mastersizer as an example of a laser diffraction instrument used to measure particle size distribution both in aerosols and in liquids for physical size classification or an Andersen Impactor for an aerodynamic size classification as described in USP.

Table I

Dosing Time (s)	Vibration KHz; μm	Frequency $t_1; t_2; E_1; E_2$ s ; V	Electrical field E V/mm	Filter Potential V_f	Machine Script
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;250;-50	250	600	Test QC 1
8	0;0	0,5;0,01;300;-50	300	650	Test QC 1
8	0;0	0,5;0,01;350;-50	350	700	Test QC 1
8	0;0	0,5;0,01;400;-50	400	750	Test QC 1
8	0;0	0,5;0,01;500;-50	500	800	Test QC 1
8	0;0	0,5;0,01;1000;-50	1000	1000	Test QC 1

10

The electro-powder de-agglomeration is performed in the electrostatic feeding device 45 where de-agglomeration and classifying of the electro-powder is performed then resulting in obtaining a majority of the powder particles being in the correct size range 0,5-5 μm for being dosed onto the device member. This de-agglomeration operation is referred to as de-agglomeration #1 or electro-powder de-agglomeration.

15

The electro-dose de-agglomeration or de-agglomeration #2 takes place when sucking off the electro-dose from the device member accompanied with a de-agglomeration of the dose in the mouthpiece.

20

Huvudboxen Kassan

De-agglomeration #2 is measured as two different airflow values, whereby the first airflow Q is according to USP and the second airflow Q_{1kPa} is at a pressure drop over the inhaler device of 1 kPa. The two different airflow values are for determining if an increase in inhalation energy has a major effect on the de-agglomeration #2. It is important to minimize the effect of the inhalation energy by adjusting the de-agglomeration #2 and the dosing properties and de-agglomeration #1 to meet the electro-dose specification.

The electro-dose de-agglomeration is measured using a mouthpiece with a nozzle in the procedure which is identical to the construction and settings inside the DPI intended to be used and with a same device member as is to be used with the DPI. The portion at the end of the mouthpiece towards the device member has to be aerodynamically correctly constructed to minimize retention.

The de-agglomeration is then calculated using the electro-powder particle size specification as input material and the High Pressure Liquid Chromatography HPLC analysis regarding particle size distribution after a standard sucking off from the device member as the output result. The de-agglomeration of the electro-dose is then calculated as percent of de-agglomerated electro-dose at 3 μm , $DD_{3\mu m}$, and 5 μm , $DD_{5\mu m}$, compared to the amount of powder less than 3 μm and 5 μm in the original electro-powder. The de-agglomeration must be more than 25 % to meet the electro-dose specification. Fig 17 and fig 18 present calculations of de-agglomeration at 3 μm and 5 μm , respectively, in a graphical representation marking the areas under the particle size distribution curves for the initial and resulting distributions respectively. The curves plotted with dots representing initial electro-powder size distribution and the curves plotted with squares representing resulting electro-dose size distribution.

The dose mass in step 250 is possible to be measured in two different ways. First option is to use a Malvern Mastersizer, where the powder is collected on a filter after analysis through the instrument. The filter is then possible to

2000 -08- 3 1

13

Huvudfaxen Kassan

analyze either using a balance, e.g. a Mettler Toledo UMT5 Ultra Microbalance or by chemical analyzes, e.g. a HPLC SpectraSYSTEM with a UV 6000 detector or any other suitable detector. A second option and also most preferable is to determine the powder mass using an Andersen 5 Impactor and analyze both the aerodynamic particle size distribution and the total mass using for instance the HPLC SpectraSYSTEM with a UV 6000 detector in accordance with USP.

To meet the electro-dose specification the mass must conform to the 10 uniformity of dose stipulated in the USP and more preferable be between 95 % < label claim < 105 % when this will be possible by a proper control regarding the electro-powder and the electrostatic dosing device together with the machine script.

15 Results from the above analysis: dose height in step 220, dose area in step 230, dose de-agglomeration in step 240 and dose mass in step 250 is noted down for calculations.

Dose density is calculated from dose mass in micrograms from step 250 20 divided by dose height in millimeters from step 220 and divided by dose area in mm² from step 230 and noted down as dose density in µg/ mm³ in step 260. Dose porosity in step 265 is here defined in percent as $D_p = 100 - 25 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ with the electro-powder density in this example being 1,4 kg/dm³. Dose mass per dose area is calculated in step 270 as dose mass in µg from step 250 divided by dose area from step 230 and noted as µg/mm². The results are then combined with the settings presented in Table I and are presented with the results in Table II below.

30 Thus, all analytical results are noted down together with input data in an analytical report as step 280 forming a decision material for the step 120 of Figure 1 determining dosing parameters. The result of this example illustrates that, in order to obtain a high quality dose with respect to de-

agglomeration in step 240, the dose porosity obtained at step 265 should be to approximately 98 % .

Table II

Test	Dose height 220 μm	Dose area 230 mm ²	Dose de-aggl. 240		Dose mass 250 μg	Dose density 260 μg/mm ³	Dose Porosity 265 %	Dose mass/area 270 μg/mm ²
			3 μm %	5 μm %				
1	196	40	80	82	77	9	99,4	1,9
2	92	40	81	84	73	20	98,6	1,8
3	76	40	81	85	75	25	98,2	1,9
4	64	40	84	87	78	30	97,9	2,0
5	69	40	83	89	77	28	98,0	1,9
6	124	40	77	84	173	35	97,5	4,3
7	137	40	74	81	214	39	97,2	5,4
8	148	40	66	73	365	62	95,6	9,1
9	135	40	63	68	415	77	94,5	10,4
10	124	40	58	64	520	105	92,5	13,0

5

The decision in step 120 determining dosing parameters is then used to make several powder dosing in a step 130 for tests and to verify that the chosen settings are correct and verified in a step 140 according to a repeated step of powder dose analysis. If the result of this powder dose analysis proves to be according to set specification for an electro-dose the settings is noted down for the continued manufacturing process.

10

On the other hand, if powder dosing according to step 130 results are not within set specification for an electro-dose, the result is in a step 145

15

returned to the step 120 of determining dosing and parameters for a new optimized parameter settings. The determining preparation of electro-dose as a step 310 in Figure 3 is then taking into account the specification of the electro-powder in step 300 and dosing parameters in step 320 to have a new set of tests for the preparation of the electro-dose. A very useful tool to optimize the electro-dose is to use a statistical planning method for the tests

20

to reduce the total amount of tests needed and fast finding the optimum preparation scheme for a desired electro-dose.

Figure 4 shows an illustrative cross section a device member with a
dissipative or conductive carrier area 14 as a dose receiver for the electro-dose and an isolative material 10, e.g. plastic, having a surface resistance greater than 10¹¹ ohms.

Figure 5 illustrates a cross section with another material as walls where the dissipative or conductive material 11 has a potential defined through an applied voltage 12 and where a conductive material is a material with a surface resistance < 10⁶ ohms or a dissipative material with a surface resistance between the conductive and the isolative material 10 < Dissipative material < 10¹¹ohms.

Figure 6 shows in an illustrative cross section a device member with a dissipative or conductive material area 24 located under or behind a thin layer approximately 10-3000 µm of isolative material 10 and where the dissipative or conductive material is having a set potential through an applied voltage 12.

Figure 7 shows an illustrative cross section of a device member with two separate dissipative or conductive materials 22 and 24 and a isolative material 10, where the dissipative or conductive material 24 forms the dose receiver of the electro-dose through a applied voltage 12 attracting the electrostatically charged electro-powder and the conductive material 22 is a conductive or dissipative material for applying a second electrical field to guide the powder to the correct position through a second applied voltage 18.

In a further illustrative embodiment similar to Figure 5 the device member material forming the dose carrier may be chosen from an isolative plastic material, which is processed before dosing by ionized air to remove

electrostatic charges from its surface. In another embodiment an isolative plastic material is processed before dosing by introducing the device member into humid air to remove electrostatic charge from its surface. In a third embodiment the device member isolative plastic material is processed before 5 dosing by combination of ionized air and humid air to remove electrostatic charges from its surface.

In still a further embodiment the device member is temporarily given a dissipative surface by applying a thin solvent layer onto its surface, e.g. 10 water, carbon dioxide or other non-toxic and FDA approved solvent. Such a solvent layer is then applied with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing removing the solvent from the device member.

15 Figure 8 shows in an illustrative example a dosing and metering set-up where a feeding device 45 for electrostatically charged electro-powder is subject to an electrical field 48 created by a separate applied potential 46 measured in V/mm and intended for transporting the electrostatically charged powder in a controlled way for dosing, metering or measuring 20 purposes. A total field acts between the device member and the electro-powder feeder 45 through two different adjusted potentials 12 and 46. Between the feeder 45 and the device member is situated a filter 44 to shield part of the device member not to be subject to dosing until the device 25 member is in the correct position and then having a transportation of electrostatically charged electro-powder particles 49 metered onto the carrier portion of the device member.

30 Figure 9 shows an illustrative example a dosing and metering set-up with a device member 11 made from a dissipative material at which powder is dosed by an applied electrical field between the feeder of electrostatically charged electro-powder 45 and the device member utilizing an electrical filter 52 with a applied make-up potential to guide the powder to the correct position onto the carrier portion of the device member. The filter potential

also serves as a possibility to control depositing on and off in a simple way by switching the applied voltage to the filter between normal potential and a much lower potential compared to the potential applied to the device member in this example. The guiding of electrostatically charged electro-powder particles 49 is then a function of applied voltage of the feeder of electrostatically charged electro-powder 49 and the voltage applied to the device member 12 and the potential of the filter 52. The filter 52 is supported by an isolative filter holding material 44.

10 Figure 10 shows in an illustrative example a dosing and metering set-up with a device member 11 in a dissipative material dosed onto by an applied electrical field between the feeder 45 of electrostatically charged electro-powder and the device member utilizing an electrical filter 52 with an applied make-up potential 59 to guide the powder to the correct position at
15 the carrier portion of the device member 11. The filter potential also serves as a possibility to control deposition on and off in a simple way by changing the potential of the filter 52. The guiding of electrostatically charged electro-powder particles 49 is then a function of applied voltage to the feeder 45 of electrostatically charged electro-powder and the applied voltage to the device
20 member 11 and the potential of the filter 52. The filter 52 is supported by an isolative filter holding material 44. The dose is possible to measure during the dosing and metering operation by using the electrometer 66 and switching the voltage 65 in front of a high voltage generator 67. During the dosing and metering operation it is also possible to control the density of the
25 electro-dose by utilizing a mechanical vibration 64 or an electrical frequency utilizing, e.g. the switching box 65 resulting in a possibility to control the electrical field and the mechanical movement according to Figures 11 and 12.

30 Figure 11 shows an example of electrical fields E_1 and E_2 applied as alternating fields at a pre-selected frequency to have the electro-powder to "dance" at the device member 11 to thereby achieve an optimum porosity for an optimum of de-agglomeration according to Figure 16. Figure 11 shows

how the total dosing time period T is divided up in periods t_1 when the electrical field is at a maximum value of E_1 and other time periods t_2 when the electrical field is at a minimum value of E_2 , whereby the time periods t_1 and t_2 are in the range $10^{-6} < t_1$, and $t_2 < 2$ seconds respectively.

5

Figure 12 illustrates an example of a set up with a mechanical vibration having a total dosing time period T and a maximum displacement of D_1 during t_1 and no displacement during the time period t_2 to make the dosed electro-powder particles to "dance" at the device member 11 and thereby, by means of a control of the applied field, having a controlled adjustment of the porosity to an optimum situation for an optimized de-agglomeration according to Figure 16, whereby the time periods t_1 and t_2 are in the range $10^{-6} < t_1$, and $t_2 < 2$ seconds, respectively.

15 Figure 13 shows a "tree" structure of powder particles at the device member 11 showing the ordering of particles of an electro-dose not being subject to adjustment of dose porosity disclosing chains of powder rising from the device member. The electro-powder particles 72 are forming "trees" of particles resulting in an extremely high porosity. The porosity of an electro-dose is calculated using the width and height of the "tree" structure together with the length to calculate the volume and then dividing the mass of the electro-dose with the volume to obtain the density of the electro-dose. The porosity is then calculated as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ in percent, where the density of the electro-powder in this example is 20 1.4 kg/dm³.

25

It should be noted that in the preferred process the carrier is turned with its receiving surface facing downwards as illustrated in Figures 13 to 15 when picking up the charged particles 72, 82 or 92. However, the process may also be performed as indicated by Figures 6 to 10.

30

Figure 14 shows an electro-dose on the device member 11 with a "sponge" structure defined as an intermediate structure of the electro-dose, where

some of the "tree" structures 82 have collapsed and are connected top to top forming a matrix with a medium to low density and less porosity through a adjusted density by electrical frequency or mechanical vibration during the dosing and metering operation thereby obtaining a lower porosity compared 5 to the "tree" structure of Figure 13.

Figure 15 shows an electro-dose at a device member 11 presenting a velvet structure 92 after being porosity adjusted with the proper electrical frequency or mechanical vibration thereby obtaining a look like a smooth 10 velvet cloth which shows much less porosity than the "sponge" structure.

Figure 16 illustrates the effect of a dose porosity adjustment in which the de-agglomeration of the electro-dose is measured at different porosities showing an optimum de-agglomeration both for particles less than 5 μm and for 15 particles less than 3 μm having a porosity in the range marked as A also indicating that the electro-dose is independent of the flow at porosities inside the range A.

In the range marked B the de-agglomeration is in a transition area and 20 showing medium flow dependence and a lower grade of de-agglomeration. In range C the porosity is lower and the powder much harder to de-agglomerate in dose de-agglomeration and also showing a strong dependence of the flow i.e. the energy level of the de-agglomeration #2 and are not suitable as an dose for inhalation and subject to optimization. $\text{DD}_{5\mu\text{m}}$ is the dose de- 25 agglomeration at 5 μm and at a differential pressure according to USP and $\text{DD}_{1\text{kPa}}$ is also according to USP but at a pressure drop over the inhaler of 1kPa.

Measurement of de-agglomeration is performed, e.g., according to Figure 19, 30 using an Andersen Impactor together with a mouthpiece and a device member in a set-up identical with the intended DPI for the electro-dose or instead of the Andersen Impactor using a Malvern Master Sizer S to measure the physical particle size. When the particle distribution is measured the de-

agglomeration can be calculated knowing the electro-powder particle size distribution.

The de-agglomeration is measured at two different rates of flow, flow-rate Q according to USP and at a flow-rate at 1 kPa pressure drop over the inhaler device according to USP. Measuring at two different flow-rates indicates if the electro-dose in the intended DPI is flow dependent or flow independent, as this may be an important aspect for the patient. If the difference in de-agglomeration is less than 25 %, when calculated as $(100 - 100 \times (\text{de-agglomeration}(Q_{1kPa}) / \text{de-agglomeration}(Q)))$, then the electro-dose meets the specifications, if the result is outside the electro-dose specifications further optimization of the electro-dose has to be performed by going back to step 310.

Figure 17 describes how the de-agglomeration at 3 μm is calculated using the initially input electro-powder under 3 μm represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area with the calculated value of the surface of the first area and multiplying by a factor 100 the de-agglomerated amount below 3 μm is obtained in percent.

Figure 18 describes how the de-agglomeration at 5 μm is calculated using the initially input electro-powder under 5 μm represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area in Figure 18 with the calculated value of the surface of the first area in Figure 18 and multiplying by a factor 100 the de-agglomerated amount below 5 μm is obtained in percent.

Huvudfoxen Kassan

Figure 19 illustrates an example of a de-agglomeration and mass measurement set-up 71 identical to the inhaler to be used to determine the particle size distribution and mass from a pre-metered electro-dose sucked up from the device member 73 through a mouthpiece 78 using an Andersen 5 Impactor 74 to determine the particle size distribution. The total pressure drop over the de-agglomeration set-up is measured with the pressure gauge 75 and the flow-rate of the air is measured with a flowmeter 76 in liters/minute. Suction may be achieved by means of a pumping device 77.

10 All measurements of the particle size distribution is measured at two different pressure drops over the inhaler device first all measurements are performed according to USP and only the pressure is changed for the measurement at a lower pressure 1kPa over the inhaler device 71 in point 79.

15 A complementary particle size distribution is also measured at 1kPa pressure drop over the de-agglomeration #2 set-up 71 indicated by the pressure gauge 79 as differential pressure to the atmosphere and then the obtained flow rate is noted down and named Q_{1kPa} . The particle size 20 distribution obtained at the flow rate Q_{1kPa} is compared with the particle size distribution obtained at the flow rate Q. the flow rate obtained by using all other settings according to the USP, and naming this flowrate Q_{1kPa} and the resulting calculated The result of the test of de-agglomeration #2 at two different pressures over the inhaler device and compared according to fig 16 25 to determine if the result meets the specification for an electro-dose and also if the de-agglomeration for 3 and 5 μm , $DD_{3\mu m, 1kPa}$ and $DD_{5\mu m, 1kPa}$ are within the specifications of the medical drug.

30 Thus the method and process according to the present disclosure will result in a very well defined electro-dose for utilization in a dry powder inhaler resulting in a small standard deviation of the doses for repeated administrations.

00 08/31 16:07 FAX +46 18 153050

AROS PATENT AB

+46 18 153050

→ PATENTVERKET

024
Ink. i. Patent- och reg.verket

22

2000-08-31

Huvudfaxen Kassan

It will be understood by those skilled in the art that various modifications and changes may be made to the present invention without departure from the scope thereof, which is defined by the appended claims.

40
00
00
00
00
00
00
00

CLAIMS

Huvudfaxon Kassan

1. An electro-dose constituting a medical powder intended for use in a dry powder inhaler, **characterized in** that the electro-dose is prepared from an electro-powder constituting an active powder substance or a dry powder medical formulation, which is metered onto a device member forming a dose carrier, giving a fine particle fraction (FPF) presenting of the order 50 % or more of its content with a particle size between 0.5-5 µm, the dose further presenting an optimized porosity of 75 to 99.9 %.
- 10 2. The electro-dose according to claim 1, **characterized in** that the metered electro-dose constitutes an electro-powder providing electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 µC/g and presents a charge decay rate constant Q₅₀ of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity a_w of less than 0.5.
- 15 3. The electro-dose according to claim 1, **characterized in** that the metered electro-powder after a mechanical vibration of the dose receiving device member during the metering operation is adjusted to a porosity presenting a value in percent between 75 and 99.9.
- 20 4. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, after analysis by a laser triangular method for a total volume calculation and a HPLC or weighing operation for determining the electro-dose mass, the porosity of the electro-dose, calculated in percent as 25 100 - 100×(Density_{electro-dose}/Density_{electro-powder}), presents a value in percent between 75 and 99.9.
- 30 5. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, onto a surface area of the device member forming a dose carrier, has a height less than 800 µm.

6. The electro-dose according to claim 1, **characterized in** that the metered electro-dose by using mechanical vibrations of the device member is adjusted to a porosity having in percent a value between 75 and 99.9.

5 7. The electro-dose according to claim 1, **characterized in** that the metered electro-dose, by using a frequency oscillation in the electrical field, is adjusted to a porosity having in percent a value between 75 and 99.9.

8. A method for preparing a metered electro-dose of electro-powder for 10 administration into the deep or upper lung airways by oral inhalation by a dry powder inhaler device, **characterized by** the steps of:

dosing a medical powder, being a preparation of chemical and biological substance forming an electro-powder onto a device member constituting a dose carrier

15 forming of a metered electro-dose bed onto the dose carrier using electrical field technology;

combining the electrical field technology with a mechanical vibration and/or an applied electrical frequency;

20 analyzing the metered electro-dose bed regarding dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity;

comparing the analysis result with predefined dosing parameters for deciding that the metered electro-dose at the dose carrier complies with the basic requirements for administration by the inhaler.

25 9. The method according to claim 8, **characterized by** the further step of controlling that the metered electro-dose has an optimized porosity of 75 to 99.9 %.

30 10. The method according to claim 8, **characterized by** the further step of utilizing mechanical vibration of the dose receiving device member during the dosing operation to adjust the metered electro-dose powder porosity to an optimized value in percent between 75 and 99.9.

Huvudforsen Kossan

11. The method according to claim 8, characterized by the further step of analyzing the metered electro-dose by a laser triangular method and a HPLC or weighing operation for a total volume calculation to determine the electro-dose mass in order to calculate the electro-dose powder porosity in

5 percent as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ obtaining an optimized value in percent between 75 and 99.

12. The method according to claim 8, characterized by the further step of preparing the metered electro-dose onto a surface area of the device member, to obtain an electro-dose height of less than 800 μm .

13. The method according to claim 12, characterized by the further step of controlling the metered electro-dose height by means of a triangular laser measuring instrument.

15 14. The method according to claim 8, characterized by the further step of additionally preparing the pre-metered electro-dose by using an oscillating electrical field to adjust the porosity of the electro-dose to an optimized value in percent of 75 to 99.9.

20 15. The method according to claim 8, characterized by the further step of preparing the electro-dose using at least one active electrical filter with a control potential switched on and off within a voltage range $V_{\text{low electrical field}} \leq V_{\text{filter}} \leq V_{\text{device member}}$ during the metering process and using an opening area per controlled opening of the active electrical filter in a range of $0.02 \leq \text{Filter opening} \leq 75 \text{ mm}^2$.

25 16. The method according to claim 8, characterized by the further step of measuring metered electro-dose mass by draining the electrostatic charge into a electrometer determining the specific charge in $\mu\text{C/g}_{\text{electro-powder}}$.

Huvudfoxen Kassan

17 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a contrast analyzing method and controlling height of the electro-dose to be less than 800 μm .

5 18 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a laser triangulation method and controlling height of the electro-dose to be less than 800 μm .

10 19 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a image analyzing method and controlling height of the electro-dose to be less than 800 μm .

15 20 The method according to claim 8, **characterized by** the further step of measuring metered electro-dose height using a combination of image analysis, laser triangulation, contrast methods to ensure a height of the electro-dose to be less than 800 μm .

21 The method according to claim 8, **characterized by** the further step of measuring electro-dose deagglomeration using a Andersen Impactor for aerodynamic particle size distribution or a Malvern Mastersizer S to determine the physical particle size distribution for a calculation and optimization of the deagglomeration of the electro-dose by changing the porosity.

25 22. A process of preparing doses of powder to be used for administration by a dry powder inhaler, **characterized in** that

a medical powder, being a preparation of a chemical and/or biological substance forming an electro-powder, is metered onto a device member constituting a dose carrier thereby forming a metered electro-dose;

30 a metered electro-dose bed is formed on the dose carrier material using electrical field technology;

Huvudfoxen Kossan

the obtained metered electro-dose bed is analyzed regarding dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity; and

a result of the analysis is compared with predefined dosing parameters for deciding that the prepared metered electro-dose of powder on the dose carrier complies with the basic requirements for administration by the inhaler.

23. The process according to claim 22, **characterized in** that electrical field technology is combined with a mechanical vibration and/or an applied electrical frequency.

24. The process according to claim 22, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by ionized air to remove electrostatic charges from its surface.

25. The process according to claim 22, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by introducing the device member into humid air to remove electrostatic charge from its surface.

26. The process according to claim 22, **characterized in** that the device member material is an isolative plastic material processed before dosing and metering by combination of ionized air and humid air to remove electrostatic charges from its surface.

27. The process according to claim 22, **characterized in** that electro-conductive material is mixed into a plastic material constituting the device member.

28. The process according to claim 22, **characterized in** that electro-conductive material is coated onto a plastic material constituting the device member.

29. The process according to claim 27 or 28, characterized in that the conductive material and the plastic material combination of the device member has a specification presenting a surface resistance of 10^3 - 10^{12} Ω, and a volume resistivity of 10^3 - 10^{12} ohm·m.

5

30. The process according to claim 22, characterized in that electro-conductive material used for the device member is obtained from any of materials such as silver powder, platinum powder, gold powder, stainless steel powder, antimony-doped tin oxide, antimony-doped silica oxide, or is a X-doped silica where X is an adamantine semiconductor, e.g., Ge, ZnO, GaSb or an octahedral semiconductor, e.g. SnSE, AgSbSe₂, InSb or carbon or any other electro-conductive material approved by FDA and possible to incorporate into plastics.

10

15 31. The process according to claim 22, characterized in that the device member is temporarily given a dissipative surface by applying a thin solvent layer onto the surface e.g. water, carbon dioxide or other non-toxic and FDA approved solvent with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing and
20 metering removing the solvent from the device member.

10
9
8
7
6
5
4
3
2
1

29

2000 -08- 3 1

ABSTRACT

Huvudfaxen Kassan

An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a metered medical powder and is formed from an electro-powder constituting an active powder substance or a dry powder medical formulation being transferred onto a device member forming a dose carrier. The electro-dose prepared from an electro-powder presents a fine particle fraction (FPF) having of the order 50 % or more of its content with a particle size between 0.5-5 µm. The electro-powder of such a metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 µC/g and presents a charge decay rate constant Q₅₀ of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity a_w of less than 0.5.

The electro-dose porosity is adjusted by means of mechanical and/or electrical vibration of the dose receiving device member during the electro-dose build-up operation to obtain an optimized porosity value in percent of 75 to 99.9 calculated as $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$. The method and the processing of electro-doses is partly illustrated by a flowchart in which steps 220 to 270 present parameters necessary to be kept under strict control.

(Fig. 2)

10
9
8
7
6
5
4
3
2
1

Ink t. Patent- och reg.verket

1/13

2000 -08- 3 1

Huvudfaxen Kassan




Fig. 1

Ink t. Patent- och ren.verket

2000 -08- 3 1

Huvudfaxen Kassan

2/13

200 Powder dose analysis

210 Powder dosing

220 Dose height

230 Dose area

240 Dose de-agglomeration

250 Dose mass

260 Dose density

265 Dose porosity

270 Dose mass/area

280 Analytical report

Fig. 2

Ink. t. Patent- och reg.verket

3/13

2000 -08- 3 1

Huvudfaxen Kassan




Fig. 3

00 08/31 16:08 FAX +46 18 153050

AROS PATENT AB

+46 18 153050

PATENTVERKET

035

Ink t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassan

4/13




Fig. 4




Fig. 5

Ink t Patent- och reg.verket

2000-08-31

5/13




Fig. 6




Fig. 7

Ink. t. Patent- och reg.verket

2000 -08- 3 1

6/13

Huvudfaxen Kassan

45




Fig. 8

7/13




Fig. 9

Ink. t Patent- och reg.verket

2000 -08- 31

8/13

Huvudfaxen Kassan




Fig.10

Ink t. Patent- och reg.verket

2000 -08- 3 1

Huvudfaxen Kassan

9/13




Fig. 11




Fig. 12

Ink t. Patent- och reg.verket

2000-08-31

10/13

Huvudfaxes Kassan




Fig. 13




Fig. 14

Ink t Patent- och reg.verket

11/13

2000 -08- 3 1

Huvudfaxen Kassan




Fig. 15




Fig. 16

Ink t Patent- och reg.verket

12/13

2000 -08- 3 1

Huvudfaxen Kossan




Fig. 17




Fig. 18

00 08/31 16:11 FAX +46 18 153050

AROS PATENT AB

→ PATENTVERKET

044

+46 18 153050

Ink t Patent- och red.verket

13/13

2000 -08- 3 1

Huvudfaxen Kassan




Fig. 19